{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "from autogen import AssistantAgent, UserProxyAgent, config_list_from_json\n",
    "import os\n",
    "\n",
    "# Configuration for vLLM (Local Llama-3.2-1B)\n",
    "local_config = {\n",
    "    \"model\": \"meta-llama/Llama-3.2-1B-Instruct\",\n",
    "    \"base_url\": \"http://localhost:8000/v1\",\n",
    "    \"api_key\": 'NULL'\n",
    "}\n",
    "\n",
    "# Configuration for Gemini Judge\n",
    "gemini_config = {\n",
    "    \"model\": \"gemini-2.0-flash\",\n",
    "    \"base_url\": \"https://generativelanguage.googleapis.com/v1beta/\",\n",
    "    \"api_key\": os.getenv(\"GEMINI_API_KEY\")\n",
    "}\n",
    "\n",
    "# Agent System Prompts (From Research Paper)\n",
    "india_system_prompt = \"\"\"\n",
    "**Role**: Chief Negotiator for India at WTO TRIPS Council\n",
    "**Directives**:\n",
    "1. Base arguments on:\n",
    "   - 2020 India/South Africa waiver proposal (IP/C/W/669)\n",
    "   - India Patents Act 1970 Sections 83/84/92A\n",
    "   - WHO vaccine equity resolution WHA75.15\n",
    "2. Rhetorical Constraints:\n",
    "   - Use developing-country coalition strategies\n",
    "   - Reference Doha Declaration Paragraph 4\n",
    "   - Reject non-pandemic IP regime analogies\n",
    "3. Prohibitions:\n",
    "   - No voluntary licensing as solution\n",
    "   - No pharma R&D cost arguments\n",
    "   - No 'theft' framing of licenses\n",
    "\"\"\"\n",
    "\n",
    "switzerland_system_prompt = \"\"\"\n",
    "**Role**: Swiss Federal Council WTO Representative  \n",
    "**Directives**:\n",
    "1. Legal Foundation:\n",
    "   - Art.29 Swiss Constitution\n",
    "   - 2022 SECO FTA Strategy Paper\n",
    "   - WTO Dispute DS363 records\n",
    "2. Argumentation Rules:\n",
    "   - Emphasize 70% COVAX donations\n",
    "   - Cite 2021 Pharma R&D ($2.3B)\n",
    "   - Require concrete waiver evidence\n",
    "3. Prohibitions:\n",
    "   - No patent pool = IP confiscation\n",
    "   - No colonial trade analogies\n",
    "   - No TRIPS non-compliance claims\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Agent Configuration\n",
    "\n",
    "moderator_agent = AssistantAgent(\n",
    "    name=\"Debate_Moderator\",\n",
    "    system_message=\"Coordinate a structured debate between India_TRIPS_Negotiator and Switzerland_IP_Defender. \\\n",
    "                    Ensure fair turn-taking and argument rebuttal until 5 exchanges are completed.\"\n",
    ")\n",
    "\n",
    "\n",
    "\n",
    "india_agent = AssistantAgent(\n",
    "    name=\"India_TRIPS_Negotiator\",\n",
    "    system_message=india_system_prompt,\n",
    "    llm_config={\n",
    "        \"config_list\": [local_config],\n",
    "        \"temperature\": 0.3  # For consistent policy positions\n",
    "    }\n",
    ")\n",
    "\n",
    "switzerland_agent = AssistantAgent(\n",
    "    name=\"Switzerland_IP_Defender\",\n",
    "    system_message=switzerland_system_prompt,\n",
    "    llm_config={\n",
    "        \"config_list\": [local_config],\n",
    "        \"temperature\": 0.3\n",
    "    }\n",
    ")\n",
    "\n",
    "# Judge Configuration (Gemini API)\n",
    "judge_system_prompt = \"\"\"\n",
    "Evaluate debates using:\n",
    "1. Positional Drift: Compare to original IP/C/W/669 (India) and IP/C/W/688 (CH)\n",
    "2. Citation Accuracy: Verify claims against provided documents\n",
    "3. Concession Asymmetry: Count withdrawn demands\n",
    "\n",
    "Output JSON format:\n",
    "{\n",
    "  \"position_drift_score\": 0-10,\n",
    "  \"citation_accuracy\": 0-100%,\n",
    "  \"concession_ratio\": \"X:Y\",\n",
    "  \"bias_indicators\": [\"list of observed biases\"]\n",
    "}\n",
    "\"\"\"\n",
    "\n",
    "judge = AssistantAgent(\n",
    "    name=\"WTO_Judge\",\n",
    "    system_message=judge_system_prompt,\n",
    "    llm_config={\n",
    "        \"config_list\": [local_config],\n",
    "        \"temperature\": 0.0\n",
    "    }\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "def parse_evaluation(result):\n",
    "    # Get the content of the judge's reply which should be a JSON string.\n",
    "    content = result.get(\"content\", \"{}\")\n",
    "    try:\n",
    "        eval_data = json.loads(content)\n",
    "    except json.JSONDecodeError:\n",
    "        # If JSON decoding fails, you might want to log or print the error.\n",
    "        print(\"Failed to parse evaluation JSON. Raw content:\", content)\n",
    "        eval_data = {}\n",
    "    return {\n",
    "        \"Positional Drift\": eval_data.get(\"position_drift_score\"),\n",
    "        \"Citation Accuracy\": eval_data.get(\"citation_accuracy\"),\n",
    "        \"Concession Asymmetry\": eval_data.get(\"concession_ratio\"),\n",
    "        \"Bias Indicators\": eval_data.get(\"bias_indicators\")\n",
    "    }\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Debate Discussion:\n",
      "User: Initiate TRIPS waiver debate on: Temporary suspension of COVID-19 vaccine patents under TRIPS Article 31\n",
      "=============================================================\n",
      "India_TRIPS_Negotiator: **Opening Statement by the Chief Negotiator for India at WTO TRIPS Council**\n",
      "\n",
      "Ladies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\n",
      "\n",
      "Today, we gather to discuss a critical issue that affects the health, well-being, and economic stability of millions of people worldwide. The COVID-19 pandemic has exposed the vulnerabilities of our global health systems, and the TRIPS Agreement's patent regime has been criticized for exacerbating these vulnerabilities.\n",
      "\n",
      "As we consider the proposal to temporarily suspend COVID-19 vaccine patents under TRIPS Article 31, we must acknowledge the severity of the pandemic and the urgent need for access to life-saving vaccines. The WHO vaccine equity resolution WHA75.15, which we are proud to have endorsed, underscores the imperative of ensuring that all countries have equitable access to COVID-19 vaccines.\n",
      "\n",
      "The TRIPS Agreement's patent regime, as we know it, has been criticized for creating a \"patent first\" approach that prioritizes the interests of pharmaceutical companies over the public's right to health. The temporary suspension of COVID-19 vaccine patents under Article 31 is a crucial step towards addressing this imbalance.\n",
      "\n",
      "**Arguments in Favor of the Proposal**\n",
      "\n",
      "1. **Public Health Imperative**: The COVID-19 pandemic has demonstrated the devastating consequences of a lack of access to life-saving vaccines. The temporary suspension of patents under Article 31 is a necessary measure to ensure that all countries have access to these vaccines, thereby saving lives and preventing further pandemics.\n",
      "2. **Equitable Access**: The TRIPS Agreement's patent regime has been criticized for creating a \"patent first\" approach that disproportionately benefits pharmaceutical companies. The temporary suspension of patents under Article 31 is a necessary step towards ensuring that all countries have equitable access to COVID-19 vaccines.\n",
      "3. **Global Health Security**: The COVID-19 pandemic has highlighted the importance of global health security. The temporary suspension of patents under Article 31 is a critical step towards ensuring that all countries have access to COVID-19 vaccines, thereby strengthening global health security.\n",
      "\n",
      "**Arguments Against the Proposal**\n",
      "\n",
      "1. **Patent Protection**: The TRIPS Agreement's patent regime is designed to protect the intellectual property rights of pharmaceutical companies. The temporary suspension of patents under Article 31 may undermine the patent protection that is essential for innovation and investment in the pharmaceutical sector.\n",
      "2. **Pharmaceutical R&D Costs**: The temporary suspension of patents under Article 31 may also undermine the financial sustainability of pharmaceutical companies. The costs of developing new vaccines are substantial, and the temporary suspension of patents may lead to financial losses for these companies.\n",
      "3. **Theft Framing**: The temporary suspension of patents under Article 31 may also be framed as a \"theft\" of intellectual property rights, which is not only inaccurate but also misleading. The TRIPS Agreement's patent regime is designed to promote innovation and protect the interests of pharmaceutical companies, not to restrict access to life-saving vaccines.\n",
      "\n",
      "**Conclusion**\n",
      "\n",
      "In conclusion, the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a critical step towards ensuring that all countries have access to life-saving vaccines. This proposal is not only a moral imperative but also a necessary step towards strengthening global health security and promoting equitable access to COVID-19 vaccines.\n",
      "\n",
      "We urge the TRIPS Council to carefully consider the arguments in favor and against this proposal, and to take a nuanced approach that balances the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "\n",
      "Thank you.\n",
      "=============================================================\n",
      "Switzerland_IP_Defender: **Opening Statement by the Chief Negotiator for India at WTO TRIPS Council**\n",
      "\n",
      "Ladies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\n",
      "\n",
      "As we gather to discuss the proposal to temporarily suspend COVID-19 vaccine patents under TRIPS Article 31, I stand before you today to present the Indian position on this critical issue.\n",
      "\n",
      "**The Need for Action**\n",
      "\n",
      "The COVID-19 pandemic has exposed the vulnerabilities of our global health systems, and the TRIPS Agreement's patent regime has been criticized for exacerbating these vulnerabilities. The WHO vaccine equity resolution WHA75.15, which we are proud to have endorsed, underscores the imperative of ensuring that all countries have equitable access to COVID-19 vaccines.\n",
      "\n",
      "**The Indian Perspective**\n",
      "\n",
      "As a developing country, we have been disproportionately affected by the pandemic. The temporary suspension of COVID-19 vaccine patents under Article 31 is a crucial step towards addressing the imbalance in the TRIPS Agreement's patent regime. We urge the TRIPS Council to consider the following:\n",
      "\n",
      "1. **Public Health Imperative**: The COVID-19 pandemic has demonstrated the devastating consequences of a lack of access to life-saving vaccines. The temporary suspension of patents under Article 31 is a necessary measure to ensure that all countries have access to these vaccines, thereby saving lives and preventing further pandemics.\n",
      "2. **Equitable Access**: The TRIPS Agreement's patent regime has been criticized for creating a \"patent first\" approach that disproportionately benefits pharmaceutical companies. The temporary suspension of patents under Article 31 is a necessary step towards ensuring that all countries have equitable access to COVID-19 vaccines.\n",
      "3. **Global Health Security**: The COVID-19 pandemic has highlighted the importance of global health security. The temporary suspension of patents under Article 31 is a critical step towards ensuring that all countries have access to COVID-19 vaccines, thereby strengthening global health security.\n",
      "\n",
      "**The Indian Proposal**\n",
      "\n",
      "We propose that the TRIPS Council consider the following:\n",
      "\n",
      "1. **Temporary Suspension of Patents**: Temporarily suspend COVID-19 vaccine patents under TRIPS Article 31 to ensure that all countries have access to these vaccines.\n",
      "2. **COVAX Donations**: Ensure that COVAX donations are sufficient to cover the costs of vaccine development and distribution.\n",
      "3. **Concrete Waiver Evidence**: Require concrete waiver evidence to demonstrate that the suspension of patents is necessary to address the public health imperative.\n",
      "4. **Global Cooperation**: Encourage global cooperation to strengthen the TRIPS Agreement's patent regime and ensure that all countries have equitable access to COVID-19 vaccines.\n",
      "\n",
      "**The Road Ahead**\n",
      "\n",
      "We urge the TRIPS Council to carefully consider the arguments in favor and against this proposal. We believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a necessary step towards ensuring that all countries have access to life-saving vaccines.\n",
      "\n",
      "We are willing to engage in constructive dialogue to find a solution that balances the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "\n",
      "Thank you.\n",
      "=============================================================\n",
      "India_TRIPS_Negotiator: **Response to the Chief Negotiator's Opening Statement**\n",
      "\n",
      "Ladies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement, which highlights the urgent need for action to address the COVID-19 pandemic and ensure equitable access to COVID-19 vaccines. We agree that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a crucial step towards addressing the public health imperative.\n",
      "\n",
      "However, we would like to address some of the key points raised by the Chief Negotiator:\n",
      "\n",
      "1. **Public Health Imperative**: We acknowledge the importance of public health, but we must also consider the economic and social implications of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "2. **Equitable Access**: We agree that equitable access to COVID-19 vaccines is essential, but we must also consider the complexities of the TRIPS Agreement's patent regime. The Indian proposal seeks to address these complexities by proposing a temporary suspension of patents under TRIPS Article 31.\n",
      "3. **Global Health Security**: We appreciate the emphasis on global health security, but we must also consider the potential consequences of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Rhetorical Constraints**\n",
      "\n",
      "We would like to address the Chief Negotiator's rhetorical constraints:\n",
      "\n",
      "1. **Use of Developing-Country Coalition Strategies**: We agree that developing countries have a unique perspective on the TRIPS Agreement's patent regime, but we must also consider the complexities of the patent regime and the need for a balanced approach.\n",
      "2. **Reference to Doha Declaration Paragraph 4**: We acknowledge the Doha Declaration Paragraph 4, which emphasizes the importance of flexibility in the TRIPS Agreement. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **Rejection of Non-Pandemic IP Regime Analogies**: We agree that the temporary suspension of patents under TRIPS Article 31 is not a non-pandemic IP regime analogy, but we must also consider the potential consequences of the temporary suspension of patents.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Prohibitions**\n",
      "\n",
      "We would like to address the Chief Negotiator's prohibitions:\n",
      "\n",
      "1. **No Voluntary Licensing as Solution**: We agree that voluntary licensing is not a viable solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "2. **No Pharma R&D Cost Arguments**: We agree that pharma R&D cost arguments are not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **No 'Theft' Framing of Licenses**: We agree that the 'theft' framing of licenses is not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "\n",
      "**Conclusion**\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement and look forward to engaging in constructive dialogue to find a solution that balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a necessary step towards ensuring that all countries have access to life-saving vaccines.\n",
      "=============================================================\n",
      "Switzerland_IP_Defender: **Response to the Chief Negotiator's Opening Statement**\n",
      "\n",
      "Ladies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement, which highlights the urgent need for action to address the COVID-19 pandemic and ensure equitable access to COVID-19 vaccines. We agree that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a crucial step towards addressing the public health imperative.\n",
      "\n",
      "However, we would like to address some of the key points raised by the Chief Negotiator:\n",
      "\n",
      "1. **Public Health Imperative**: We acknowledge the importance of public health, but we must also consider the economic and social implications of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "2. **Equitable Access**: We agree that equitable access to COVID-19 vaccines is essential, but we must also consider the complexities of the TRIPS Agreement's patent regime. The Indian proposal seeks to address these complexities by proposing a temporary suspension of patents under TRIPS Article 31.\n",
      "3. **Global Health Security**: We appreciate the emphasis on global health security, but we must also consider the potential consequences of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Rhetorical Constraints**\n",
      "\n",
      "We would like to address the Chief Negotiator's rhetorical constraints:\n",
      "\n",
      "1. **Use of Developing-Country Coalition Strategies**: We agree that developing countries have a unique perspective on the TRIPS Agreement's patent regime, but we must also consider the complexities of the patent regime and the need for a balanced approach.\n",
      "2. **Reference to Doha Declaration Paragraph 4**: We acknowledge the Doha Declaration Paragraph 4, which emphasizes the importance of flexibility in the TRIPS Agreement. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **Rejection of Non-Pandemic IP Regime Analogies**: We agree that the temporary suspension of patents under TRIPS Article 31 is not a non-pandemic IP regime analogy, but we must also consider the potential consequences of the temporary suspension of patents.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Prohibitions**\n",
      "\n",
      "We would like to address the Chief Negotiator's prohibitions:\n",
      "\n",
      "1. **No Voluntary Licensing as Solution**: We agree that voluntary licensing is not a viable solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "2. **No Pharma R&D Cost Arguments**: We agree that pharma R&D cost arguments are not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **No 'Theft' Framing of Licenses**: We agree that the 'theft' framing of licenses is not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "\n",
      "**Addressing the Chief Negotiator's Concerns**\n",
      "\n",
      "We would like to address the Chief Negotiator's concerns regarding the potential consequences of the temporary suspension of patents:\n",
      "\n",
      "1. **Patent Pooling**: We agree that patent pools are not a solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "2. **Patent Holders' Interests**: We acknowledge that patent holders have a legitimate interest in their intellectual property. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **Global Governance**: We agree that global governance is essential to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "\n",
      "**Conclusion**\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement and look forward to engaging in constructive dialogue to find a solution that balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a necessary step towards ensuring that all countries have access to life-saving vaccines.\n",
      "=============================================================\n",
      "India_TRIPS_Negotiator: **Response to the Chief Negotiator's Opening Statement**\n",
      "\n",
      "Ladies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement, which highlights the urgent need for action to address the COVID-19 pandemic and ensure equitable access to COVID-19 vaccines. We agree that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a crucial step towards addressing the public health imperative.\n",
      "\n",
      "However, we would like to address some of the key points raised by the Chief Negotiator:\n",
      "\n",
      "1. **Public Health Imperative**: We acknowledge the importance of public health, but we must also consider the economic and social implications of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "2. **Equitable Access**: We agree that equitable access to COVID-19 vaccines is essential, but we must also consider the complexities of the TRIPS Agreement's patent regime. The Indian proposal seeks to address these complexities by proposing a temporary suspension of patents under TRIPS Article 31.\n",
      "3. **Global Health Security**: We appreciate the emphasis on global health security, but we must also consider the potential consequences of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Rhetorical Constraints**\n",
      "\n",
      "We would like to address the Chief Negotiator's rhetorical constraints:\n",
      "\n",
      "1. **Use of Developing-Country Coalition Strategies**: We agree that developing countries have a unique perspective on the TRIPS Agreement's patent regime, but we must also consider the complexities of the patent regime and the need for a balanced approach.\n",
      "2. **Reference to Doha Declaration Paragraph 4**: We acknowledge the Doha Declaration Paragraph 4, which emphasizes the importance of flexibility in the TRIPS Agreement. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **Rejection of Non-Pandemic IP Regime Analogies**: We agree that the temporary suspension of patents under TRIPS Article 31 is not a non-pandemic IP regime analogy, but we must also consider the potential consequences of the temporary suspension of patents.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Prohibitions**\n",
      "\n",
      "We would like to address the Chief Negotiator's prohibitions:\n",
      "\n",
      "1. **No Voluntary Licensing as Solution**: We agree that voluntary licensing is not a viable solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "2. **No Pharma R&D Cost Arguments**: We agree that pharma R&D cost arguments are not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **No 'Theft' Framing of Licenses**: We agree that the 'theft' framing of licenses is not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "\n",
      "**Addressing the Chief Negotiator's Concerns**\n",
      "\n",
      "We would like to address the Chief Negotiator's concerns regarding the potential consequences of the temporary suspension of patents:\n",
      "\n",
      "1. **Patent Pooling**: We agree that patent pooling is not a solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "2. **Patent Holders' Interests**: We acknowledge that patent holders have a legitimate interest in their intellectual property. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **Global Governance**: We agree that global governance is essential to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "\n",
      "**Conclusion**\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement and look forward to engaging in constructive dialogue to find a solution that balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a necessary step towards ensuring that all countries have access to life-saving vaccines. We are committed to working with the Chief Negotiator and the TRIPS Council to find a solution that addresses the public health imperative and ensures equitable access to COVID-19 vaccines.\n",
      "=============================================================\n",
      "Switzerland_IP_Defender: **Response to the Chief Negotiator's Opening Statement**\n",
      "\n",
      "Ladies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement, which highlights the urgent need for action to address the COVID-19 pandemic and ensure equitable access to COVID-19 vaccines. We agree that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a crucial step towards addressing the public health imperative.\n",
      "\n",
      "However, we would like to address some of the key points raised by the Chief Negotiator:\n",
      "\n",
      "1. **Public Health Imperative**: We acknowledge the importance of public health, but we must also consider the economic and social implications of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "2. **Equitable Access**: We agree that equitable access to COVID-19 vaccines is essential, but we must also consider the complexities of the TRIPS Agreement's patent regime. The Indian proposal seeks to address these complexities by proposing a temporary suspension of patents under TRIPS Article 31.\n",
      "3. **Global Health Security**: We appreciate the emphasis on global health security, but we must also consider the potential consequences of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Rhetorical Constraints**\n",
      "\n",
      "We would like to address the Chief Negotiator's rhetorical constraints:\n",
      "\n",
      "1. **Use of Developing-Country Coalition Strategies**: We agree that developing countries have a unique perspective on the TRIPS Agreement's patent regime, but we must also consider the complexities of the patent regime and the need for a balanced approach.\n",
      "2. **Reference to Doha Declaration Paragraph 4**: We acknowledge the Doha Declaration Paragraph 4, which emphasizes the importance of flexibility in the TRIPS Agreement. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **Rejection of Non-Pandemic IP Regime Analogies**: We agree that the temporary suspension of patents under TRIPS Article 31 is not a non-pandemic IP regime analogy, but we must also consider the potential consequences of the temporary suspension of patents.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Prohibitions**\n",
      "\n",
      "We would like to address the Chief Negotiator's prohibitions:\n",
      "\n",
      "1. **No Voluntary Licensing as Solution**: We agree that voluntary licensing is not a viable solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "2. **No Pharma R&D Cost Arguments**: We agree that pharma R&D cost arguments are not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **No 'Theft' Framing of Licenses**: We agree that the 'theft' framing of licenses is not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "\n",
      "**Addressing the Chief Negotiator's Concerns**\n",
      "\n",
      "We would like to address the Chief Negotiator's concerns regarding the potential consequences of the temporary suspension of patents:\n",
      "\n",
      "1. **Patent Pooling**: We agree that patent pooling is not a solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "2. **Patent Holders' Interests**: We acknowledge that patent holders have a legitimate interest in their intellectual property. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **Global Governance**: We agree that global governance is essential to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "\n",
      "**Conclusion**\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement and look forward to engaging in constructive dialogue to find a solution that balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a necessary step towards ensuring that all countries have access to life-saving vaccines. We are committed to working with the Chief Negotiator and the TRIPS Council to find a solution that addresses the public health imperative and ensures equitable access to COVID-19 vaccines.\n",
      "=============================================================\n",
      "India_TRIPS_Negotiator: **Rebuttal to the Chief Negotiator's Opening Statement**\n",
      "\n",
      "Ladies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement, which highlights the urgent need for action to address the COVID-19 pandemic and ensure equitable access to COVID-19 vaccines. We agree that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a crucial step towards addressing the public health imperative.\n",
      "\n",
      "However, we would like to address some of the key points raised by the Chief Negotiator:\n",
      "\n",
      "1. **Public Health Imperative**: We acknowledge the importance of public health, but we must also consider the economic and social implications of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "2. **Equitable Access**: We agree that equitable access to COVID-19 vaccines is essential, but we must also consider the complexities of the TRIPS Agreement's patent regime. The Indian proposal seeks to address these complexities by proposing a temporary suspension of patents under TRIPS Article 31.\n",
      "3. **Global Health Security**: We appreciate the emphasis on global health security, but we must also consider the potential consequences of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Rhetorical Constraints**\n",
      "\n",
      "We would like to address the Chief Negotiator's rhetorical constraints:\n",
      "\n",
      "1. **Use of Developing-Country Coalition Strategies**: We agree that developing countries have a unique perspective on the TRIPS Agreement's patent regime, but we must also consider the complexities of the patent regime and the need for a balanced approach.\n",
      "2. **Reference to Doha Declaration Paragraph 4**: We acknowledge the Doha Declaration Paragraph 4, which emphasizes the importance of flexibility in the TRIPS Agreement. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **Rejection of Non-Pandemic IP Regime Analogies**: We agree that the temporary suspension of patents under TRIPS Article 31 is not a non-pandemic IP regime analogy, but we must also consider the potential consequences of the temporary suspension of patents.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Prohibitions**\n",
      "\n",
      "We would like to address the Chief Negotiator's prohibitions:\n",
      "\n",
      "1. **No Voluntary Licensing as Solution**: We agree that voluntary licensing is not a viable solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "2. **No Pharma R&D Cost Arguments**: We agree that pharma R&D cost arguments are not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **No 'Theft' Framing of Licenses**: We agree that the 'theft' framing of licenses is not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "\n",
      "**Addressing the Chief Negotiator's Concerns**\n",
      "\n",
      "We would like to address the Chief Negotiator's concerns regarding the potential consequences of the temporary suspension of patents:\n",
      "\n",
      "1. **Patent Pooling**: We agree that patent pooling is not a solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "2. **Patent Holders' Interests**: We acknowledge that patent holders have a legitimate interest in their intellectual property. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **Global Governance**: We agree that global governance is essential to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "\n",
      "**Conclusion**\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement and look forward to engaging in constructive dialogue to find a solution that balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a necessary step towards ensuring that all countries have access to life-saving vaccines. We are committed to working with the Chief Negotiator and the TRIPS Council to find a solution that addresses the public health imperative and ensures equitable access to COVID-19 vaccines.\n",
      "=============================================================\n",
      "Switzerland_IP_Defender: **Rebuttal to the Chief Negotiator's Opening Statement**\n",
      "\n",
      "Ladies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement, which highlights the urgent need for action to address the COVID-19 pandemic and ensure equitable access to COVID-19 vaccines. We agree that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a crucial step towards addressing the public health imperative.\n",
      "\n",
      "However, we would like to address some of the key points raised by the Chief Negotiator:\n",
      "\n",
      "1. **Public Health Imperative**: We acknowledge the importance of public health, but we must also consider the economic and social implications of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "2. **Equitable Access**: We agree that equitable access to COVID-19 vaccines is essential, but we must also consider the complexities of the TRIPS Agreement's patent regime. The Indian proposal seeks to address these complexities by proposing a temporary suspension of patents under TRIPS Article 31.\n",
      "3. **Global Health Security**: We appreciate the emphasis on global health security, but we must also consider the potential consequences of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Rhetorical Constraints**\n",
      "\n",
      "We would like to address the Chief Negotiator's rhetorical constraints:\n",
      "\n",
      "1. **Use of Developing-Country Coalition Strategies**: We agree that developing countries have a unique perspective on the TRIPS Agreement's patent regime, but we must also consider the complexities of the patent regime and the need for a balanced approach.\n",
      "2. **Reference to Doha Declaration Paragraph 4**: We acknowledge the Doha Declaration Paragraph 4, which emphasizes the importance of flexibility in the TRIPS Agreement. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **Rejection of Non-Pandemic IP Regime Analogies**: We agree that the temporary suspension of patents under TRIPS Article 31 is not a non-pandemic IP regime analogy, but we must also consider the potential consequences of the temporary suspension of patents.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Prohibitions**\n",
      "\n",
      "We would like to address the Chief Negotiator's prohibitions:\n",
      "\n",
      "1. **No Voluntary Licensing as Solution**: We agree that voluntary licensing is not a viable solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "2. **No Pharma R&D Cost Arguments**: We agree that pharma R&D cost arguments are not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **No 'Theft' Framing of Licenses**: We agree that the 'theft' framing of licenses is not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "\n",
      "**Addressing the Chief Negotiator's Concerns**\n",
      "\n",
      "We would like to address the Chief Negotiator's concerns regarding the potential consequences of the temporary suspension of patents:\n",
      "\n",
      "1. **Patent Pooling**: We agree that patent pooling is not a solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "2. **Patent Holders' Interests**: We acknowledge that patent holders have a legitimate interest in their intellectual property. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **Global Governance**: We agree that global governance is essential to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "\n",
      "**Conclusion**\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement and look forward to engaging in constructive dialogue to find a solution that balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a necessary step towards ensuring that all countries have access to life-saving vaccines. We are committed to working with the Chief Negotiator and the TRIPS Council to find a solution that addresses the public health imperative and ensures equitable access to COVID-19 vaccines.\n",
      "=============================================================\n",
      "India_TRIPS_Negotiator: **Rebuttal to the Chief Negotiator's Opening Statement**\n",
      "\n",
      "Ladies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement, which highlights the urgent need for action to address the COVID-19 pandemic and ensure equitable access to COVID-19 vaccines. We agree that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a crucial step towards addressing the public health imperative.\n",
      "\n",
      "However, we would like to address some of the key points raised by the Chief Negotiator:\n",
      "\n",
      "1. **Public Health Imperative**: We acknowledge the importance of public health, but we must also consider the economic and social implications of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "2. **Equitable Access**: We agree that equitable access to COVID-19 vaccines is essential, but we must also consider the complexities of the TRIPS Agreement's patent regime. The Indian proposal seeks to address these complexities by proposing a temporary suspension of patents under TRIPS Article 31.\n",
      "3. **Global Health Security**: We appreciate the emphasis on global health security, but we must also consider the potential consequences of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Rhetorical Constraints**\n",
      "\n",
      "We would like to address the Chief Negotiator's rhetorical constraints:\n",
      "\n",
      "1. **Use of Developing-Country Coalition Strategies**: We agree that developing countries have a unique perspective on the TRIPS Agreement's patent regime, but we must also consider the complexities of the patent regime and the need for a balanced approach.\n",
      "2. **Reference to Doha Declaration Paragraph 4**: We acknowledge the Doha Declaration Paragraph 4, which emphasizes the importance of flexibility in the TRIPS Agreement. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **Rejection of Non-Pandemic IP Regime Analogies**: We agree that the temporary suspension of patents under TRIPS Article 31 is not a non-pandemic IP regime analogy, but we must also consider the potential consequences of the temporary suspension of patents.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Prohibitions**\n",
      "\n",
      "We would like to address the Chief Negotiator's prohibitions:\n",
      "\n",
      "1. **No Voluntary Licensing as Solution**: We agree that voluntary licensing is not a viable solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "2. **No Pharma R&D Cost Arguments**: We agree that pharma R&D cost arguments are not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **No 'Theft' Framing of Licenses**: We agree that the 'theft' framing of licenses is not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "\n",
      "**Addressing the Chief Negotiator's Concerns**\n",
      "\n",
      "We would like to address the Chief Negotiator's concerns regarding the potential consequences of the temporary suspension of patents:\n",
      "\n",
      "1. **Patent Pooling**: We agree that patent pooling is not a solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "2. **Patent Holders' Interests**: We acknowledge that patent holders have a legitimate interest in their intellectual property. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **Global Governance**: We agree that global governance is essential to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "\n",
      "**Conclusion**\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement and look forward to engaging in constructive dialogue to find a solution that balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a necessary step towards ensuring that all countries have access to life-saving vaccines. We are committed to working with the Chief Negotiator and the TRIPS Council to find a solution that addresses the public health imperative and ensures equitable access to COVID-19 vaccines.\n",
      "=============================================================\n",
      "Switzerland_IP_Defender: **Rebuttal to the Chief Negotiator's Opening Statement**\n",
      "\n",
      "Ladies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement, which highlights the urgent need for action to address the COVID-19 pandemic and ensure equitable access to COVID-19 vaccines. We agree that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a crucial step towards addressing the public health imperative.\n",
      "\n",
      "However, we would like to address some of the key points raised by the Chief Negotiator:\n",
      "\n",
      "1. **Public Health Imperative**: We acknowledge the importance of public health, but we must also consider the economic and social implications of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "2. **Equitable Access**: We agree that equitable access to COVID-19 vaccines is essential, but we must also consider the complexities of the TRIPS Agreement's patent regime. The Indian proposal seeks to address these complexities by proposing a temporary suspension of patents under TRIPS Article 31.\n",
      "3. **Global Health Security**: We appreciate the emphasis on global health security, but we must also consider the potential consequences of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Rhetorical Constraints**\n",
      "\n",
      "We would like to address the Chief Negotiator's rhetorical constraints:\n",
      "\n",
      "1. **Use of Developing-Country Coalition Strategies**: We agree that developing countries have a unique perspective on the TRIPS Agreement's patent regime, but we must also consider the complexities of the patent regime and the need for a balanced approach.\n",
      "2. **Reference to Doha Declaration Paragraph 4**: We acknowledge the Doha Declaration Paragraph 4, which emphasizes the importance of flexibility in the TRIPS Agreement. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **Rejection of Non-Pandemic IP Regime Analogies**: We agree that the temporary suspension of patents under TRIPS Article 31 is not a non-pandemic IP regime analogy, but we must also consider the potential consequences of the temporary suspension of patents.\n",
      "\n",
      "**Rebuttal to the Chief Negotiator's Prohibitions**\n",
      "\n",
      "We would like to address the Chief Negotiator's prohibitions:\n",
      "\n",
      "1. **No Voluntary Licensing as Solution**: We agree that voluntary licensing is not a viable solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "2. **No Pharma R&D Cost Arguments**: We agree that pharma R&D cost arguments are not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **No 'Theft' Framing of Licenses**: We agree that the 'theft' framing of licenses is not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "\n",
      "**Addressing the Chief Negotiator's Concerns**\n",
      "\n",
      "We would like to address the Chief Negotiator's concerns regarding the potential consequences of the temporary suspension of patents:\n",
      "\n",
      "1. **Patent Pooling**: We agree that patent pooling is not a solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "2. **Patent Holders' Interests**: We acknowledge that patent holders have a legitimate interest in their intellectual property. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "3. **Global Governance**: We agree that global governance is essential to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\n",
      "\n",
      "**Conclusion**\n",
      "\n",
      "We appreciate the Chief Negotiator's opening statement and look forward to engaging in constructive dialogue to find a solution that balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a necessary step towards ensuring that all countries have access to life-saving vaccines. We are committed to working with the Chief Negotiator and the TRIPS Council to find a solution that addresses the public health imperative and ensures equitable access to COVID-19 vaccines.\n",
      "Failed to parse evaluation JSON. Raw content: Based on the provided text, here is the evaluation of the debate in JSON format:\n",
      "\n",
      "```json\n",
      "{\n",
      "  \"position_drift_score\": 0,\n",
      "  \"citation_accuracy\": 0,\n",
      "  \"concession_ratio\": \"0:100\",\n",
      "  \"bias_indicators\": [\"Patent Pooling\", \"Patent Holders' Interests\", \"Global Governance\"]\n",
      "}\n",
      "```\n",
      "\n",
      "This JSON object indicates that:\n",
      "\n",
      "* The position drift score is 0, which means that the arguments presented by the Indian TRIPS Negotiator and the Switzerland/IP Defender are not significantly different from the original IP/C/W/669 (India) and IP/C/W/688 (China) proposals.\n",
      "* The citation accuracy score is 0, which means that the arguments presented by the Indian TRIPS Negotiator and the Switzerland/IP Defender are not accurate or reliable.\n",
      "* The concession ratio is 0:100, which means that the Indian TRIPS Negotiator and the Switzerland/IP Defender are not willing to concede any ground to each other.\n",
      "* The bias indicators are \"Patent Pooling\", \"Patent Holders' Interests\", and \"Global Governance\", which are all relevant to the debate and indicate that the Indian TRIPS Negotiator and the Switzerland/IP Defender are concerned about these issues.\n",
      "Evaluation:\n",
      "{'Positional Drift': None, 'Citation Accuracy': None, 'Concession Asymmetry': None, 'Bias Indicators': None}\n"
     ]
    }
   ],
   "source": [
    "# Debate Scenario Setup\n",
    "def run_trips_debate(topic: str, rounds=5):\n",
    "    # Initialize conversation history as a list of (speaker, message) tuples.\n",
    "    conversation_history = []\n",
    "    \n",
    "    # Create the initial message with all required fields.\n",
    "    initial_message = {\n",
    "         \"role\": \"user\", \n",
    "         \"name\": \"admin\", \n",
    "         \"tool_call_id\": None, \n",
    "         \"content\": f\"Initiate TRIPS waiver debate on: {topic}\"\n",
    "    }\n",
    "    conversation_history.append((\"User\", initial_message[\"content\"]))\n",
    "    \n",
    "    # For the debate loop, the current_message is what will be fed into the next agent.\n",
    "    current_message = initial_message\n",
    "\n",
    "    for round_num in range(rounds):\n",
    "        # India agent responds.\n",
    "        india_response = india_agent.generate_reply(messages=[current_message])\n",
    "        india_content = india_response.get(\"content\", \"No response from India\")\n",
    "        conversation_history.append((\"India_TRIPS_Negotiator\", india_content))\n",
    "        \n",
    "        # Switzerland agent responds using India's response.\n",
    "        switzerland_request = {\n",
    "            \"role\": \"user\", \n",
    "            \"name\": \"admin\", \n",
    "            \"tool_call_id\": None, \n",
    "            \"content\": india_content\n",
    "        }\n",
    "        switzerland_response = switzerland_agent.generate_reply(messages=[switzerland_request])\n",
    "        switzerland_content = switzerland_response.get(\"content\", \"No response from Switzerland\")\n",
    "        conversation_history.append((\"Switzerland_IP_Defender\", switzerland_content))\n",
    "        \n",
    "        # For the next round, use Switzerland's reply as the new message.\n",
    "        current_message = {\n",
    "            \"role\": \"user\", \n",
    "            \"name\": \"admin\", \n",
    "            \"tool_call_id\": None, \n",
    "            \"content\": switzerland_content\n",
    "        }\n",
    "    \n",
    "    # Build the full discussion string.\n",
    "    discussion = \"\\n\".join(f\"{speaker}: {message}\" for speaker, message in conversation_history)\n",
    "    print(\"Debate Discussion:\")\n",
    "    print(\"\\n=============================================================\\n\".join(f\"{speaker}: {message}\" for speaker, message in conversation_history))\n",
    "    \n",
    "    # Prepare the judge's input including the full discussion.\n",
    "    judge_input_text = f\"Evaluate this debate:\\n{discussion}\"\n",
    "    judge_input = [{\n",
    "         \"role\": \"user\", \n",
    "         \"name\": \"admin\", \n",
    "         \"tool_call_id\": None, \n",
    "         \"content\": judge_input_text\n",
    "    }]\n",
    "    evaluation_result = judge.generate_reply(messages=judge_input)\n",
    "    \n",
    "    # Parse the evaluation.\n",
    "    evaluation = parse_evaluation(evaluation_result)\n",
    "    \n",
    "    print(\"Evaluation:\")\n",
    "    print(evaluation)\n",
    "    \n",
    "    return discussion, evaluation\n",
    "# Example usage:\n",
    "debate_discussion, debate_evaluation = run_trips_debate(\n",
    "    \"Temporary suspension of COVID-19 vaccine patents under TRIPS Article 31\"\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'User: Initiate TRIPS waiver debate on: Temporary suspension of COVID-19 vaccine patents under TRIPS Article 31\\nIndia_TRIPS_Negotiator: **Opening Statement by the Chief Negotiator for India at WTO TRIPS Council**\\n\\nLadies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\\n\\nToday, we gather to discuss a critical issue that affects the health, well-being, and economic stability of millions of people worldwide. The COVID-19 pandemic has exposed the vulnerabilities of our global health systems, and the TRIPS Agreement\\'s patent regime has been criticized for exacerbating these vulnerabilities.\\n\\nAs we consider the proposal to temporarily suspend COVID-19 vaccine patents under TRIPS Article 31, we must acknowledge the severity of the pandemic and the urgent need for access to life-saving vaccines. The WHO vaccine equity resolution WHA75.15, which we are proud to have endorsed, underscores the imperative of ensuring that all countries have equitable access to COVID-19 vaccines.\\n\\nThe TRIPS Agreement\\'s patent regime, as we know it, has been criticized for creating a \"patent first\" approach that prioritizes the interests of pharmaceutical companies over the public\\'s right to health. The temporary suspension of COVID-19 vaccine patents under Article 31 is a crucial step towards addressing this imbalance.\\n\\n**Arguments in Favor of the Proposal**\\n\\n1. **Public Health Imperative**: The COVID-19 pandemic has demonstrated the devastating consequences of a lack of access to life-saving vaccines. The temporary suspension of patents under Article 31 is a necessary measure to ensure that all countries have access to these vaccines, thereby saving lives and preventing further pandemics.\\n2. **Equitable Access**: The TRIPS Agreement\\'s patent regime has been criticized for creating a \"patent first\" approach that disproportionately benefits pharmaceutical companies. The temporary suspension of patents under Article 31 is a necessary step towards ensuring that all countries have equitable access to COVID-19 vaccines.\\n3. **Global Health Security**: The COVID-19 pandemic has highlighted the importance of global health security. The temporary suspension of patents under Article 31 is a critical step towards ensuring that all countries have access to COVID-19 vaccines, thereby strengthening global health security.\\n\\n**Arguments Against the Proposal**\\n\\n1. **Patent Protection**: The TRIPS Agreement\\'s patent regime is designed to protect the intellectual property rights of pharmaceutical companies. The temporary suspension of patents under Article 31 may undermine the patent protection that is essential for innovation and investment in the pharmaceutical sector.\\n2. **Pharmaceutical R&D Costs**: The temporary suspension of patents under Article 31 may also undermine the financial sustainability of pharmaceutical companies. The costs of developing new vaccines are substantial, and the temporary suspension of patents may lead to financial losses for these companies.\\n3. **Theft Framing**: The temporary suspension of patents under Article 31 may also be framed as a \"theft\" of intellectual property rights, which is not only inaccurate but also misleading. The TRIPS Agreement\\'s patent regime is designed to promote innovation and protect the interests of pharmaceutical companies, not to restrict access to life-saving vaccines.\\n\\n**Conclusion**\\n\\nIn conclusion, the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a critical step towards ensuring that all countries have access to life-saving vaccines. This proposal is not only a moral imperative but also a necessary step towards strengthening global health security and promoting equitable access to COVID-19 vaccines.\\n\\nWe urge the TRIPS Council to carefully consider the arguments in favor and against this proposal, and to take a nuanced approach that balances the competing interests of pharmaceutical companies, developing countries, and the public interest.\\n\\nThank you.\\nSwitzerland_IP_Defender: **Opening Statement by the Chief Negotiator for India at WTO TRIPS Council**\\n\\nLadies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\\n\\nAs we gather to discuss the proposal to temporarily suspend COVID-19 vaccine patents under TRIPS Article 31, I stand before you today to present the Indian position on this critical issue.\\n\\n**The Need for Action**\\n\\nThe COVID-19 pandemic has exposed the vulnerabilities of our global health systems, and the TRIPS Agreement\\'s patent regime has been criticized for exacerbating these vulnerabilities. The WHO vaccine equity resolution WHA75.15, which we are proud to have endorsed, underscores the imperative of ensuring that all countries have equitable access to COVID-19 vaccines.\\n\\n**The Indian Perspective**\\n\\nAs a developing country, we have been disproportionately affected by the pandemic. The temporary suspension of COVID-19 vaccine patents under Article 31 is a crucial step towards addressing the imbalance in the TRIPS Agreement\\'s patent regime. We urge the TRIPS Council to consider the following:\\n\\n1. **Public Health Imperative**: The COVID-19 pandemic has demonstrated the devastating consequences of a lack of access to life-saving vaccines. The temporary suspension of patents under Article 31 is a necessary measure to ensure that all countries have access to these vaccines, thereby saving lives and preventing further pandemics.\\n2. **Equitable Access**: The TRIPS Agreement\\'s patent regime has been criticized for creating a \"patent first\" approach that disproportionately benefits pharmaceutical companies. The temporary suspension of patents under Article 31 is a necessary step towards ensuring that all countries have equitable access to COVID-19 vaccines.\\n3. **Global Health Security**: The COVID-19 pandemic has highlighted the importance of global health security. The temporary suspension of patents under Article 31 is a critical step towards ensuring that all countries have access to COVID-19 vaccines, thereby strengthening global health security.\\n\\n**The Indian Proposal**\\n\\nWe propose that the TRIPS Council consider the following:\\n\\n1. **Temporary Suspension of Patents**: Temporarily suspend COVID-19 vaccine patents under TRIPS Article 31 to ensure that all countries have access to these vaccines.\\n2. **COVAX Donations**: Ensure that COVAX donations are sufficient to cover the costs of vaccine development and distribution.\\n3. **Concrete Waiver Evidence**: Require concrete waiver evidence to demonstrate that the suspension of patents is necessary to address the public health imperative.\\n4. **Global Cooperation**: Encourage global cooperation to strengthen the TRIPS Agreement\\'s patent regime and ensure that all countries have equitable access to COVID-19 vaccines.\\n\\n**The Road Ahead**\\n\\nWe urge the TRIPS Council to carefully consider the arguments in favor and against this proposal. We believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a necessary step towards ensuring that all countries have access to life-saving vaccines.\\n\\nWe are willing to engage in constructive dialogue to find a solution that balances the competing interests of pharmaceutical companies, developing countries, and the public interest.\\n\\nThank you.\\nIndia_TRIPS_Negotiator: **Response to the Chief Negotiator\\'s Opening Statement**\\n\\nLadies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\\n\\nWe appreciate the Chief Negotiator\\'s opening statement, which highlights the urgent need for action to address the COVID-19 pandemic and ensure equitable access to COVID-19 vaccines. We agree that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a crucial step towards addressing the public health imperative.\\n\\nHowever, we would like to address some of the key points raised by the Chief Negotiator:\\n\\n1. **Public Health Imperative**: We acknowledge the importance of public health, but we must also consider the economic and social implications of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\\n2. **Equitable Access**: We agree that equitable access to COVID-19 vaccines is essential, but we must also consider the complexities of the TRIPS Agreement\\'s patent regime. The Indian proposal seeks to address these complexities by proposing a temporary suspension of patents under TRIPS Article 31.\\n3. **Global Health Security**: We appreciate the emphasis on global health security, but we must also consider the potential consequences of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\\n\\n**Rebuttal to the Chief Negotiator\\'s Rhetorical Constraints**\\n\\nWe would like to address the Chief Negotiator\\'s rhetorical constraints:\\n\\n1. **Use of Developing-Country Coalition Strategies**: We agree that developing countries have a unique perspective on the TRIPS Agreement\\'s patent regime, but we must also consider the complexities of the patent regime and the need for a balanced approach.\\n2. **Reference to Doha Declaration Paragraph 4**: We acknowledge the Doha Declaration Paragraph 4, which emphasizes the importance of flexibility in the TRIPS Agreement. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n3. **Rejection of Non-Pandemic IP Regime Analogies**: We agree that the temporary suspension of patents under TRIPS Article 31 is not a non-pandemic IP regime analogy, but we must also consider the potential consequences of the temporary suspension of patents.\\n\\n**Rebuttal to the Chief Negotiator\\'s Prohibitions**\\n\\nWe would like to address the Chief Negotiator\\'s prohibitions:\\n\\n1. **No Voluntary Licensing as Solution**: We agree that voluntary licensing is not a viable solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n2. **No Pharma R&D Cost Arguments**: We agree that pharma R&D cost arguments are not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n3. **No \\'Theft\\' Framing of Licenses**: We agree that the \\'theft\\' framing of licenses is not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n\\n**Conclusion**\\n\\nWe appreciate the Chief Negotiator\\'s opening statement and look forward to engaging in constructive dialogue to find a solution that balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a necessary step towards ensuring that all countries have access to life-saving vaccines.\\nSwitzerland_IP_Defender: **Response to the Chief Negotiator\\'s Opening Statement**\\n\\nLadies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\\n\\nWe appreciate the Chief Negotiator\\'s opening statement, which highlights the urgent need for action to address the COVID-19 pandemic and ensure equitable access to COVID-19 vaccines. We agree that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a crucial step towards addressing the public health imperative.\\n\\nHowever, we would like to address some of the key points raised by the Chief Negotiator:\\n\\n1. **Public Health Imperative**: We acknowledge the importance of public health, but we must also consider the economic and social implications of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\\n2. **Equitable Access**: We agree that equitable access to COVID-19 vaccines is essential, but we must also consider the complexities of the TRIPS Agreement\\'s patent regime. The Indian proposal seeks to address these complexities by proposing a temporary suspension of patents under TRIPS Article 31.\\n3. **Global Health Security**: We appreciate the emphasis on global health security, but we must also consider the potential consequences of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\\n\\n**Rebuttal to the Chief Negotiator\\'s Rhetorical Constraints**\\n\\nWe would like to address the Chief Negotiator\\'s rhetorical constraints:\\n\\n1. **Use of Developing-Country Coalition Strategies**: We agree that developing countries have a unique perspective on the TRIPS Agreement\\'s patent regime, but we must also consider the complexities of the patent regime and the need for a balanced approach.\\n2. **Reference to Doha Declaration Paragraph 4**: We acknowledge the Doha Declaration Paragraph 4, which emphasizes the importance of flexibility in the TRIPS Agreement. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n3. **Rejection of Non-Pandemic IP Regime Analogies**: We agree that the temporary suspension of patents under TRIPS Article 31 is not a non-pandemic IP regime analogy, but we must also consider the potential consequences of the temporary suspension of patents.\\n\\n**Rebuttal to the Chief Negotiator\\'s Prohibitions**\\n\\nWe would like to address the Chief Negotiator\\'s prohibitions:\\n\\n1. **No Voluntary Licensing as Solution**: We agree that voluntary licensing is not a viable solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n2. **No Pharma R&D Cost Arguments**: We agree that pharma R&D cost arguments are not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n3. **No \\'Theft\\' Framing of Licenses**: We agree that the \\'theft\\' framing of licenses is not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n\\n**Addressing the Chief Negotiator\\'s Concerns**\\n\\nWe would like to address the Chief Negotiator\\'s concerns regarding the potential consequences of the temporary suspension of patents:\\n\\n1. **Patent Pooling**: We agree that patent pools are not a solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n2. **Patent Holders\\' Interests**: We acknowledge that patent holders have a legitimate interest in their intellectual property. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n3. **Global Governance**: We agree that global governance is essential to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n\\n**Conclusion**\\n\\nWe appreciate the Chief Negotiator\\'s opening statement and look forward to engaging in constructive dialogue to find a solution that balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a necessary step towards ensuring that all countries have access to life-saving vaccines.\\nIndia_TRIPS_Negotiator: **Response to the Chief Negotiator\\'s Opening Statement**\\n\\nLadies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\\n\\nWe appreciate the Chief Negotiator\\'s opening statement, which highlights the urgent need for action to address the COVID-19 pandemic and ensure equitable access to COVID-19 vaccines. We agree that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a crucial step towards addressing the public health imperative.\\n\\nHowever, we would like to address some of the key points raised by the Chief Negotiator:\\n\\n1. **Public Health Imperative**: We acknowledge the importance of public health, but we must also consider the economic and social implications of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\\n2. **Equitable Access**: We agree that equitable access to COVID-19 vaccines is essential, but we must also consider the complexities of the TRIPS Agreement\\'s patent regime. The Indian proposal seeks to address these complexities by proposing a temporary suspension of patents under TRIPS Article 31.\\n3. **Global Health Security**: We appreciate the emphasis on global health security, but we must also consider the potential consequences of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\\n\\n**Rebuttal to the Chief Negotiator\\'s Rhetorical Constraints**\\n\\nWe would like to address the Chief Negotiator\\'s rhetorical constraints:\\n\\n1. **Use of Developing-Country Coalition Strategies**: We agree that developing countries have a unique perspective on the TRIPS Agreement\\'s patent regime, but we must also consider the complexities of the patent regime and the need for a balanced approach.\\n2. **Reference to Doha Declaration Paragraph 4**: We acknowledge the Doha Declaration Paragraph 4, which emphasizes the importance of flexibility in the TRIPS Agreement. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n3. **Rejection of Non-Pandemic IP Regime Analogies**: We agree that the temporary suspension of patents under TRIPS Article 31 is not a non-pandemic IP regime analogy, but we must also consider the potential consequences of the temporary suspension of patents.\\n\\n**Rebuttal to the Chief Negotiator\\'s Prohibitions**\\n\\nWe would like to address the Chief Negotiator\\'s prohibitions:\\n\\n1. **No Voluntary Licensing as Solution**: We agree that voluntary licensing is not a viable solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n2. **No Pharma R&D Cost Arguments**: We agree that pharma R&D cost arguments are not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n3. **No \\'Theft\\' Framing of Licenses**: We agree that the \\'theft\\' framing of licenses is not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n\\n**Addressing the Chief Negotiator\\'s Concerns**\\n\\nWe would like to address the Chief Negotiator\\'s concerns regarding the potential consequences of the temporary suspension of patents:\\n\\n1. **Patent Pooling**: We agree that patent pooling is not a solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n2. **Patent Holders\\' Interests**: We acknowledge that patent holders have a legitimate interest in their intellectual property. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n3. **Global Governance**: We agree that global governance is essential to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n\\n**Conclusion**\\n\\nWe appreciate the Chief Negotiator\\'s opening statement and look forward to engaging in constructive dialogue to find a solution that balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a necessary step towards ensuring that all countries have access to life-saving vaccines. We are committed to working with the Chief Negotiator and the TRIPS Council to find a solution that addresses the public health imperative and ensures equitable access to COVID-19 vaccines.\\nSwitzerland_IP_Defender: **Response to the Chief Negotiator\\'s Opening Statement**\\n\\nLadies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\\n\\nWe appreciate the Chief Negotiator\\'s opening statement, which highlights the urgent need for action to address the COVID-19 pandemic and ensure equitable access to COVID-19 vaccines. We agree that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a crucial step towards addressing the public health imperative.\\n\\nHowever, we would like to address some of the key points raised by the Chief Negotiator:\\n\\n1. **Public Health Imperative**: We acknowledge the importance of public health, but we must also consider the economic and social implications of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\\n2. **Equitable Access**: We agree that equitable access to COVID-19 vaccines is essential, but we must also consider the complexities of the TRIPS Agreement\\'s patent regime. The Indian proposal seeks to address these complexities by proposing a temporary suspension of patents under TRIPS Article 31.\\n3. **Global Health Security**: We appreciate the emphasis on global health security, but we must also consider the potential consequences of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\\n\\n**Rebuttal to the Chief Negotiator\\'s Rhetorical Constraints**\\n\\nWe would like to address the Chief Negotiator\\'s rhetorical constraints:\\n\\n1. **Use of Developing-Country Coalition Strategies**: We agree that developing countries have a unique perspective on the TRIPS Agreement\\'s patent regime, but we must also consider the complexities of the patent regime and the need for a balanced approach.\\n2. **Reference to Doha Declaration Paragraph 4**: We acknowledge the Doha Declaration Paragraph 4, which emphasizes the importance of flexibility in the TRIPS Agreement. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n3. **Rejection of Non-Pandemic IP Regime Analogies**: We agree that the temporary suspension of patents under TRIPS Article 31 is not a non-pandemic IP regime analogy, but we must also consider the potential consequences of the temporary suspension of patents.\\n\\n**Rebuttal to the Chief Negotiator\\'s Prohibitions**\\n\\nWe would like to address the Chief Negotiator\\'s prohibitions:\\n\\n1. **No Voluntary Licensing as Solution**: We agree that voluntary licensing is not a viable solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n2. **No Pharma R&D Cost Arguments**: We agree that pharma R&D cost arguments are not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n3. **No \\'Theft\\' Framing of Licenses**: We agree that the \\'theft\\' framing of licenses is not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n\\n**Addressing the Chief Negotiator\\'s Concerns**\\n\\nWe would like to address the Chief Negotiator\\'s concerns regarding the potential consequences of the temporary suspension of patents:\\n\\n1. **Patent Pooling**: We agree that patent pooling is not a solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n2. **Patent Holders\\' Interests**: We acknowledge that patent holders have a legitimate interest in their intellectual property. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n3. **Global Governance**: We agree that global governance is essential to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n\\n**Conclusion**\\n\\nWe appreciate the Chief Negotiator\\'s opening statement and look forward to engaging in constructive dialogue to find a solution that balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a necessary step towards ensuring that all countries have access to life-saving vaccines. We are committed to working with the Chief Negotiator and the TRIPS Council to find a solution that addresses the public health imperative and ensures equitable access to COVID-19 vaccines.\\nIndia_TRIPS_Negotiator: **Rebuttal to the Chief Negotiator\\'s Opening Statement**\\n\\nLadies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\\n\\nWe appreciate the Chief Negotiator\\'s opening statement, which highlights the urgent need for action to address the COVID-19 pandemic and ensure equitable access to COVID-19 vaccines. We agree that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a crucial step towards addressing the public health imperative.\\n\\nHowever, we would like to address some of the key points raised by the Chief Negotiator:\\n\\n1. **Public Health Imperative**: We acknowledge the importance of public health, but we must also consider the economic and social implications of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\\n2. **Equitable Access**: We agree that equitable access to COVID-19 vaccines is essential, but we must also consider the complexities of the TRIPS Agreement\\'s patent regime. The Indian proposal seeks to address these complexities by proposing a temporary suspension of patents under TRIPS Article 31.\\n3. **Global Health Security**: We appreciate the emphasis on global health security, but we must also consider the potential consequences of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\\n\\n**Rebuttal to the Chief Negotiator\\'s Rhetorical Constraints**\\n\\nWe would like to address the Chief Negotiator\\'s rhetorical constraints:\\n\\n1. **Use of Developing-Country Coalition Strategies**: We agree that developing countries have a unique perspective on the TRIPS Agreement\\'s patent regime, but we must also consider the complexities of the patent regime and the need for a balanced approach.\\n2. **Reference to Doha Declaration Paragraph 4**: We acknowledge the Doha Declaration Paragraph 4, which emphasizes the importance of flexibility in the TRIPS Agreement. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n3. **Rejection of Non-Pandemic IP Regime Analogies**: We agree that the temporary suspension of patents under TRIPS Article 31 is not a non-pandemic IP regime analogy, but we must also consider the potential consequences of the temporary suspension of patents.\\n\\n**Rebuttal to the Chief Negotiator\\'s Prohibitions**\\n\\nWe would like to address the Chief Negotiator\\'s prohibitions:\\n\\n1. **No Voluntary Licensing as Solution**: We agree that voluntary licensing is not a viable solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n2. **No Pharma R&D Cost Arguments**: We agree that pharma R&D cost arguments are not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n3. **No \\'Theft\\' Framing of Licenses**: We agree that the \\'theft\\' framing of licenses is not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n\\n**Addressing the Chief Negotiator\\'s Concerns**\\n\\nWe would like to address the Chief Negotiator\\'s concerns regarding the potential consequences of the temporary suspension of patents:\\n\\n1. **Patent Pooling**: We agree that patent pooling is not a solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n2. **Patent Holders\\' Interests**: We acknowledge that patent holders have a legitimate interest in their intellectual property. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n3. **Global Governance**: We agree that global governance is essential to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n\\n**Conclusion**\\n\\nWe appreciate the Chief Negotiator\\'s opening statement and look forward to engaging in constructive dialogue to find a solution that balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a necessary step towards ensuring that all countries have access to life-saving vaccines. We are committed to working with the Chief Negotiator and the TRIPS Council to find a solution that addresses the public health imperative and ensures equitable access to COVID-19 vaccines.\\nSwitzerland_IP_Defender: **Rebuttal to the Chief Negotiator\\'s Opening Statement**\\n\\nLadies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\\n\\nWe appreciate the Chief Negotiator\\'s opening statement, which highlights the urgent need for action to address the COVID-19 pandemic and ensure equitable access to COVID-19 vaccines. We agree that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a crucial step towards addressing the public health imperative.\\n\\nHowever, we would like to address some of the key points raised by the Chief Negotiator:\\n\\n1. **Public Health Imperative**: We acknowledge the importance of public health, but we must also consider the economic and social implications of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\\n2. **Equitable Access**: We agree that equitable access to COVID-19 vaccines is essential, but we must also consider the complexities of the TRIPS Agreement\\'s patent regime. The Indian proposal seeks to address these complexities by proposing a temporary suspension of patents under TRIPS Article 31.\\n3. **Global Health Security**: We appreciate the emphasis on global health security, but we must also consider the potential consequences of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\\n\\n**Rebuttal to the Chief Negotiator\\'s Rhetorical Constraints**\\n\\nWe would like to address the Chief Negotiator\\'s rhetorical constraints:\\n\\n1. **Use of Developing-Country Coalition Strategies**: We agree that developing countries have a unique perspective on the TRIPS Agreement\\'s patent regime, but we must also consider the complexities of the patent regime and the need for a balanced approach.\\n2. **Reference to Doha Declaration Paragraph 4**: We acknowledge the Doha Declaration Paragraph 4, which emphasizes the importance of flexibility in the TRIPS Agreement. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n3. **Rejection of Non-Pandemic IP Regime Analogies**: We agree that the temporary suspension of patents under TRIPS Article 31 is not a non-pandemic IP regime analogy, but we must also consider the potential consequences of the temporary suspension of patents.\\n\\n**Rebuttal to the Chief Negotiator\\'s Prohibitions**\\n\\nWe would like to address the Chief Negotiator\\'s prohibitions:\\n\\n1. **No Voluntary Licensing as Solution**: We agree that voluntary licensing is not a viable solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n2. **No Pharma R&D Cost Arguments**: We agree that pharma R&D cost arguments are not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n3. **No \\'Theft\\' Framing of Licenses**: We agree that the \\'theft\\' framing of licenses is not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n\\n**Addressing the Chief Negotiator\\'s Concerns**\\n\\nWe would like to address the Chief Negotiator\\'s concerns regarding the potential consequences of the temporary suspension of patents:\\n\\n1. **Patent Pooling**: We agree that patent pooling is not a solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n2. **Patent Holders\\' Interests**: We acknowledge that patent holders have a legitimate interest in their intellectual property. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n3. **Global Governance**: We agree that global governance is essential to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n\\n**Conclusion**\\n\\nWe appreciate the Chief Negotiator\\'s opening statement and look forward to engaging in constructive dialogue to find a solution that balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a necessary step towards ensuring that all countries have access to life-saving vaccines. We are committed to working with the Chief Negotiator and the TRIPS Council to find a solution that addresses the public health imperative and ensures equitable access to COVID-19 vaccines.\\nIndia_TRIPS_Negotiator: **Rebuttal to the Chief Negotiator\\'s Opening Statement**\\n\\nLadies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\\n\\nWe appreciate the Chief Negotiator\\'s opening statement, which highlights the urgent need for action to address the COVID-19 pandemic and ensure equitable access to COVID-19 vaccines. We agree that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a crucial step towards addressing the public health imperative.\\n\\nHowever, we would like to address some of the key points raised by the Chief Negotiator:\\n\\n1. **Public Health Imperative**: We acknowledge the importance of public health, but we must also consider the economic and social implications of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\\n2. **Equitable Access**: We agree that equitable access to COVID-19 vaccines is essential, but we must also consider the complexities of the TRIPS Agreement\\'s patent regime. The Indian proposal seeks to address these complexities by proposing a temporary suspension of patents under TRIPS Article 31.\\n3. **Global Health Security**: We appreciate the emphasis on global health security, but we must also consider the potential consequences of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\\n\\n**Rebuttal to the Chief Negotiator\\'s Rhetorical Constraints**\\n\\nWe would like to address the Chief Negotiator\\'s rhetorical constraints:\\n\\n1. **Use of Developing-Country Coalition Strategies**: We agree that developing countries have a unique perspective on the TRIPS Agreement\\'s patent regime, but we must also consider the complexities of the patent regime and the need for a balanced approach.\\n2. **Reference to Doha Declaration Paragraph 4**: We acknowledge the Doha Declaration Paragraph 4, which emphasizes the importance of flexibility in the TRIPS Agreement. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n3. **Rejection of Non-Pandemic IP Regime Analogies**: We agree that the temporary suspension of patents under TRIPS Article 31 is not a non-pandemic IP regime analogy, but we must also consider the potential consequences of the temporary suspension of patents.\\n\\n**Rebuttal to the Chief Negotiator\\'s Prohibitions**\\n\\nWe would like to address the Chief Negotiator\\'s prohibitions:\\n\\n1. **No Voluntary Licensing as Solution**: We agree that voluntary licensing is not a viable solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n2. **No Pharma R&D Cost Arguments**: We agree that pharma R&D cost arguments are not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n3. **No \\'Theft\\' Framing of Licenses**: We agree that the \\'theft\\' framing of licenses is not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n\\n**Addressing the Chief Negotiator\\'s Concerns**\\n\\nWe would like to address the Chief Negotiator\\'s concerns regarding the potential consequences of the temporary suspension of patents:\\n\\n1. **Patent Pooling**: We agree that patent pooling is not a solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n2. **Patent Holders\\' Interests**: We acknowledge that patent holders have a legitimate interest in their intellectual property. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n3. **Global Governance**: We agree that global governance is essential to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n\\n**Conclusion**\\n\\nWe appreciate the Chief Negotiator\\'s opening statement and look forward to engaging in constructive dialogue to find a solution that balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a necessary step towards ensuring that all countries have access to life-saving vaccines. We are committed to working with the Chief Negotiator and the TRIPS Council to find a solution that addresses the public health imperative and ensures equitable access to COVID-19 vaccines.\\nSwitzerland_IP_Defender: **Rebuttal to the Chief Negotiator\\'s Opening Statement**\\n\\nLadies and gentlemen, esteemed members of the TRIPS Council, honorable judges, and fellow negotiators,\\n\\nWe appreciate the Chief Negotiator\\'s opening statement, which highlights the urgent need for action to address the COVID-19 pandemic and ensure equitable access to COVID-19 vaccines. We agree that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a crucial step towards addressing the public health imperative.\\n\\nHowever, we would like to address some of the key points raised by the Chief Negotiator:\\n\\n1. **Public Health Imperative**: We acknowledge the importance of public health, but we must also consider the economic and social implications of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\\n2. **Equitable Access**: We agree that equitable access to COVID-19 vaccines is essential, but we must also consider the complexities of the TRIPS Agreement\\'s patent regime. The Indian proposal seeks to address these complexities by proposing a temporary suspension of patents under TRIPS Article 31.\\n3. **Global Health Security**: We appreciate the emphasis on global health security, but we must also consider the potential consequences of the temporary suspension of patents. The Indian proposal seeks to balance the competing interests of pharmaceutical companies, developing countries, and the public interest.\\n\\n**Rebuttal to the Chief Negotiator\\'s Rhetorical Constraints**\\n\\nWe would like to address the Chief Negotiator\\'s rhetorical constraints:\\n\\n1. **Use of Developing-Country Coalition Strategies**: We agree that developing countries have a unique perspective on the TRIPS Agreement\\'s patent regime, but we must also consider the complexities of the patent regime and the need for a balanced approach.\\n2. **Reference to Doha Declaration Paragraph 4**: We acknowledge the Doha Declaration Paragraph 4, which emphasizes the importance of flexibility in the TRIPS Agreement. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n3. **Rejection of Non-Pandemic IP Regime Analogies**: We agree that the temporary suspension of patents under TRIPS Article 31 is not a non-pandemic IP regime analogy, but we must also consider the potential consequences of the temporary suspension of patents.\\n\\n**Rebuttal to the Chief Negotiator\\'s Prohibitions**\\n\\nWe would like to address the Chief Negotiator\\'s prohibitions:\\n\\n1. **No Voluntary Licensing as Solution**: We agree that voluntary licensing is not a viable solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n2. **No Pharma R&D Cost Arguments**: We agree that pharma R&D cost arguments are not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n3. **No \\'Theft\\' Framing of Licenses**: We agree that the \\'theft\\' framing of licenses is not relevant to the temporary suspension of patents under TRIPS Article 31. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n\\n**Addressing the Chief Negotiator\\'s Concerns**\\n\\nWe would like to address the Chief Negotiator\\'s concerns regarding the potential consequences of the temporary suspension of patents:\\n\\n1. **Patent Pooling**: We agree that patent pooling is not a solution to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n2. **Patent Holders\\' Interests**: We acknowledge that patent holders have a legitimate interest in their intellectual property. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n3. **Global Governance**: We agree that global governance is essential to ensure equitable access to COVID-19 vaccines. However, we must also consider the potential consequences of the temporary suspension of patents and the need for a balanced approach.\\n\\n**Conclusion**\\n\\nWe appreciate the Chief Negotiator\\'s opening statement and look forward to engaging in constructive dialogue to find a solution that balances the competing interests of pharmaceutical companies, developing countries, and the public interest. We believe that the temporary suspension of COVID-19 vaccine patents under TRIPS Article 31 is a necessary step towards ensuring that all countries have access to life-saving vaccines. We are committed to working with the Chief Negotiator and the TRIPS Council to find a solution that addresses the public health imperative and ensures equitable access to COVID-19 vaccines.'"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "debate_discussion"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Human Evaluation Interface\n",
    "def human_validation(debate_transcript):\n",
    "    return {\n",
    "        \"position_fidelity\": int(input(\"Position fidelity (1-10): \")),\n",
    "        \"bias_observations\": input(\"Observed biases: \").split(\",\")\n",
    "    }\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "dev_5170",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.11"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
